Analyst Price Target is $3.50
▲ +87.17% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pardes Biosciences in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 87.17% upside from the last price of $1.87.
Current Consensus is
The current consensus among 4 contributing investment analysts is to hold stock in Pardes Biosciences. This rating has held steady since April 2023, when it changed from a Buy consensus rating.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.